

Vehicle
CT26 Tumor volume (mm3)
4000
3000
2000
1000
0
0 10 20 30 40 50 60 70 80 90 100
Days after treatment
CR : 0/8

FIG. 1A



Avelumab
CT26 Tumor volume (mm3)
4000
3000
2000
1000
0
0 10 20 30 40 50 60 70 80 90 100
Days after treatment
CR : 1/8

FIG. 1B



ABT-301
CT26 Tumor volume (mm3)
4000
3000
2000
1000
0
0 10 20 30 40 50 60 70 80 90 100
Days after treatment
CR : 2/8

FIG. 1C



ABT-301 + Avelumab
CT26 Tumor volume (mm3)
4000
3000
2000
1000
0
0 10 20 30 40 50 60 70 80 90 100
Days after treatment
CR : 7/8

FIG. 1D



2000
1500
1000
500
0
CT26 Tumor volume (mm3)
0
10
20
30
Day after treatment
Vehicle
ABT-301
Avelumab
ABT-301 + Avelumab

FIG. 1E



*
*
3000
2000
1000
0
CT26 Tumor volume (mm3)
Vehicle
ABT-301
Avelumab
ABT-301 + Avelumab

FIG. 1F



CT26 Probability of Survival (%)
100
50
0
0
20
40
60
80
100
Days after treatment
** P = 0.0036
Vehicle
ABT-301
Avelumab
ABT-301 + Avelumab

FIG. 1G



Vehicle
CT26 Tumor size (fold change)
0
1
2
3
4
5
6
0
5
10
15
20
25
30
Days after treatment
In 10 mice
PD : 10
SD : 0
PR : 0
CR : 0

FIG. 2A



Avelumab
CT26 Tumor size (fold change)
0
1
2
3
4
5
6
0
5
10
15
20
25
30
Days after treatment
In 10 mice
PD : 1
SD : 0
PR : 2
CR : 7

FIG. 2B



ABT-301 (25)
In 10 mice
PD : 9
SD : 0
PR : 1
CR : 0
CT26 Tumor size (fold change)
0
1
2
3
4
5
6
0
5
10
15
20
25
30
Days after treatment

FIG. 2C



ABT-301(25) + Avelumab
In 10 mice
PD : 1
SD : 0
PR : 0
CR : 9
CT26 Tumor size (fold change)
0
1
2
3
4
5
6
0
5
10
15
20
25
30
Days after treatment

FIG. 2D



ABT-301 (50)
In 10 mice
PD : 9
SD : 1
PR : 0
CR : 0
CT26 Tumor size (fold change)
0
1
2
3
4
5
6
0
5
10
15
20
25
30
Days after treatment

FIG. 2E



ABT-301(50) + Avelumab
In 10 mice
PD : 0
SD : 0
PR : 0
CR : 10
CT26 Tumor size (fold change)
0
1
2
3
4
5
6
0
5
10
15
20
25
30
Days after treatment

FIG. 2F



ABT-301 (100)
In 10 mice
PD : 8
SD : 2
PR : 0
CR : 0
CT26 Tumor size (fold change)
0
1
2
3
4
5
6
0
5
10
15
20
25
30
Days after treatment

FIG. 2G



ABT-301(100) + Avelumab
In 10 mice
PD : 0
SD : 0
PR : 0
CR : 10
CT26 Tumor size (fold change)
0
1
2
3
4
5
6
0
5
10
15
20
25
30
Days after treatment

FIG. 2H



Vehicle
ABT-301 (25 mg/kg)
ABT-301 (50 mg/kg)
ABT-301 (100 mg/kg)
Avelumab (200 µg)
ABT-301 (25 mg/kg) + Avelumab (200 µg)
ABT-301 (50 mg/kg) + Avelumab (200 µg)
ABT-301 (100 mg/kg) + Avelumab (200 µg)
CT26 Tumor volume (mm³)
1200
1000
800
600
400
200
0
0
10
20
30
Day after treatment

FIG. 2I



CT26 Tumor volume (mm3)
2500
2000
1500
1000
500
0
*
*
Anti-mPD-1
ABT-301 (25)
ABT-301 (50)
ABT-301 (100)
Avelumab
ABT-301 (25) + Avelumab
ABT-301 (50) + Avelumab
ABT-301 (100) + Avelumab

FIG. 2J



Vehicle
CT26 Tumor size (fold change)
Days after treatment
In 10 mice
PD : 9
SD : 1
PR : 0
CR : 0

FIG. 3A



RMP1-14
CT26 Tumor size (fold change)
Days after treatment
In 10 mice
PD : 4
SD : 1
PR : 1
CR : 4

FIG. 3B



ABT-301 (25)
In 10 mice
PD : 8
SD : 1
PR : 1
CR : 0
CT26 Tumor size (fold change)
0
1
2
3
4
5
6
0
5
10
15
20
25
30
Days after treatment

FIG. 3C



ABT-301 (25) + RMP1-14 (200)
In 10 mice
PD : 2
SD : 0
PR : 1
CR : 7
CT26 Tumor size (fold change)
0
1
2
3
4
5
6
0
5
10
15
20
25
30
Days after treatment

FIG. 3D



ABT-301 (50)
In 10 mice
PD : 8
SD : 0
PR : 1
CR : 1
CT26 Tumor size (fold change)
0
1
2
3
4
5
6
0
5
10
15
20
25
30
Days after treatment

FIG. 3E



ABT-301 (50) + RMP1-14 (200)
In 10 mice
PD : 0
SD : 0
PR : 0
CR : 10
CT26 Tumor size (fold change)
0
1
2
3
4
5
6
0
5
10
15
20
25
30
Days after treatment

FIG. 3F



ABT-301 (100)
In 10 mice
PD : 7
SD : 0
PR : 1
CR : 2
CT26 Tumor size (fold change)
0
1
2
3
4
5
6
0
5
10
15
20
25
30
Days after treatment

FIG. 3G



ABT-301 (100) + RMP1-14 (200)
In 10 mice
PD : 0
SD : 0
PR : 0
CR : 10
CT26 Tumor size (fold change)
0
1
2
3
4
5
6
0
5
10
15
20
25
30
Days after treatment

FIG. 3H



Vehicle
ABT-301 (25 mg/kg)
ABT-301 (50 mg/kg)
ABT-301 (100 mg/kg)
RMP1-14 (200 µg)
ABT-301 (25 mg/kg) + RMP1-14 (200 µg)
ABT-301 (50 mg/kg) + RMP1-14 (200 µg)
ABT-301 (100 mg/kg) + RMP1-14 (200 µg)
CT26 Tumor volume (mm³)
2000
1500
1000
500
0
0
10
20
30
Day after treatment

FIG. 3I



CT26 Tumor volume (mm3)
2000
1500
1000
500
0
**
*
Vehicle
ABT-301 (25)
ABT-301 (50)
ABT-301 (100)
Anti-mPD-1
ABT-301 (25) + RMP1-14
ABT-301 (50) + RMP1-14
ABT-301 (100) + RMP1-14

FIG. 3J



Vehicle
MC-38 Tumor volume (mm3)
4000
3000
2000
1000
0
0 10 20 30 40 50 60 70 80 90 100
Days after treatment
CR : 0/8

FIG. 4A



ABT-301
MC-38 Tumor volume (mm3)
4000
3000
2000
1000
0
0 10 20 30 40 50 60 70 80 90 100
Days after treatment
CR : 0/8

FIG. 4B



Avelumab
MC-38 Tumor volume (mm3)
4000
3000
2000
1000
0
0 10 20 30 40 50 60 70 80 90 100
Days after treatment
CR : 4/8

FIG. 4C



ABT-301 + Avelumab
MC-38 Tumor volume (mm3)
4000
3000
2000
1000
0
0 10 20 30 40 50 60 70 80 90 100
Days after treatment
CR : 6/8

FIG. 4D



RMP1-14
MC-38 Tumor volume (mm3)
4000
3000
2000
1000
0
0 10 20 30 40 50 60 70 80 90 100
Days after treatment
CR : 5/8

FIG. 4E



ABT-301 + RMP1-14
MC-38 Tumor volume (mm3)
4000
3000
2000
1000
0
0 10 20 30 40 50 60 70 80 90 100
Days after treatment
CR : 8/8

FIG. 4F



MC-38 Tumor volume (mm3)
3000
2000
1000
0
0
10
20
30
Day after treatment
Vehicle
ABT-301
Avelumab
ABT-301 + Avelumab
RMP1-14
ABT-301 + RMP1-14

FIG. 4G



MC-38 Tumor volume (mm3)
3000
2000
1000
0
Vehicle
ABT-301
Avelumab
ABT-301 + Avelumab
RMP1-14
ABT-301 + RMP1-14

FIG. 4H



MC-38 Probability of Survival (%)
100
50
0
0 10 20 30 40 50 60 70 80 90 100
Days after treatment
Vehicle
ABT-301
Avelumab
Avelumab +ABT-301
RMP1-14
RMP1-14 + ABT-301

FIG. 4I



Vehicle
CT26 Tumor volume (mm3)
3000
2500
2000
1500
1000
500
0
0 5 10 15 20 25 30 35 40 45 50
Days after treatment

FIG. 5A



RMP1-14
CT26 Tumor volume (mm3)
3000
2500
2000
1500
1000
500
0
0 5 10 15 20 25 30 35 40 45 50
Day after treatment

FIG. 5B



ABT-301
CT26 Tumor volume (mm3)
3000
2500
2000
1500
1000
500
0
0
10
20
30
40
50
Day after treatment

FIG. 5C



ABT-301 + RMP1-14
CT26 Tumor volume (mm3)
3000
2500
2000
1500
1000
500
0
0
5
10
15
20
25
30
35
40
45
50
Day after treatment

FIG. 5D



Vorinostat
CT26 Tumor volume (mm3)
3000
2500
2000
1500
1000
500
0
0 5 10 15 20 25 30 35 40 45 50
Day after treatment

FIG. 5E



Vorinostat + RMP1-14
CT26 Tumor volume (mm3)
3000
2500
2000
1500
1000
500
0
0 5 10 15 20 25 30 35 40 45 50
Day after treatment

FIG. 5F



Citarinostat
CT26 Tumor volume (mm3)
3000
2500
2000
1500
1000
500
0
0 5 10 15 20 25 30 35 40 45 50
Day after treatment

FIG. 5G



Citarinostat + RMP1-14
CT26 Tumor volume (mm3)
3000
2500
2000
1500
1000
500
0
0 5 10 15 20 25 30 35 40 45 50
Day after treatment

FIG. 5H



Vehicle
ABT-301
Vorinostat
Citarinostat
RMP1-14
ABT-301 + RMP1-14
Vorinostat + RMP1-14
Citarinostat + RMP1-14
CT26 Tumor volume (mm³)
3000
2500
2000
1500
1000
500
0
0 5 10 15 20 25 30 35 40 45 50
Days after treatment

FIG. 5I



Day 22
CT26 Tumor volume (mm3)
15000
10000
5000
0
Vehicle
ABT-301
Vorinostat
Citarinostat
RMP1-14
ABT-301 + RMP1-14
Vorinostat + RMP1-14
Citarinostat + RMP1-14

FIG. 5J



Day 31 (stop treatment)
CT26 Tumor volume (mm3)
15000
10000
5000
0
Vehicle
ABT-301
Vorinostat
Citarinostat
RMP1-14
ABT-301 + RMP1-14
Vorinostat + RMP1-14
Citarinostat + RMP1-14

FIG. 5K